My understanding - bangs and Merck positioned their product at as high as 15x the price point of the inferior product (our royalty was 15-20%) so it was used as a blocking product - ie you can have the better one but it costs so much why not buy old familiar here at the same old price.
Affy - I think GCs disappointment was more to do with the original intention to use MnG via eBio and/or flowcytomics range and then the takeover and discontinuation delayed everything but in the long run MnG has been included in more products but their sales need to ramp up?
Feel free to correct the errors in that anyone as my understanding was light and memory is poor or details.
affymetrix, bangs & merck deals, page-2
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $46.90M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $23.42K | 1.233M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1142321 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 339684 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| ADO (ASX) Chart |